IDEAS home Printed from
   My bibliography  Save this article

The Production Of Medicines In Romania After 1990. What'S The Reason For Imports?


  • Unita Lucian

    () (University of Oradea, Faculty of Medicine and Pharmacy)

  • Straciuc Oreste

    (University of Oradea, Faculty of Medicine and Pharmacy)

  • Maghiar Teodor Traian

    (University of Oradea, Faculty of Medicine and Pharmacy)

  • Uivarosan Diana

    (University of Oradea, Faculty of Medicine and Pharmacy)


Since 1990, Romania turned itself slowly but surely, from a large drugs producer, which has used to supplydrugs to the whole former Council for Mutual Economic Assistance Member States, and with a net positive trade balance in medicine sector, into a large drugs importer, trying hardly to attract investors which could produce medicines not only for the Romanian domestic market, but also for all other Eastern European markets, Ukraine, Russia and Turkey. This paper focuses on the empirical analisys of the medicines production sector in Romania after 1990, aiming to emphasises the factors which have mostly affected this industry, in correlation with different interests and reasons which determined the increasing imports of drugs during the last years, by underlying at the same time, the role of the new public authority in charge of supervising the distribution and import of medicines in Romania, The National Medicines Administration (NMA). The paper relevance relies in the fact that Romania registered during the last years drug imports of an average of 1.7 billion euros, while the drug exports were only around 0,1 billions euros, according to the computations made on the data provided by the Romanian Institute of National Statistics (INS). The most imported products are patent drugs, which are more expensive than those produced by the domestic manufactured. At the same time, Romania registered an increase of the pharmaceutical market of around 20% only since its EU integration, this market proven to be largely driven by expensive products. Our research conducted to the conclusion that the Romanian resort authorities have to immediately adopt measures meant to limit consumption of expensive drugs, on the one side, and to reinforce the domestic manufacturers on the other side, even by attracting major investors in this sector. We have also identified that there is a large competitiveness for Romanian medicine products on the international market, due to its production costs (Romania still is a low cost economy in this sector), as well as due to its tradition.

Suggested Citation

  • Unita Lucian & Straciuc Oreste & Maghiar Teodor Traian & Uivarosan Diana, 2011. "The Production Of Medicines In Romania After 1990. What'S The Reason For Imports?," Annals of Faculty of Economics, University of Oradea, Faculty of Economics, vol. 1(2), pages 124-130, December.
  • Handle: RePEc:ora:journl:v:1:y:2011:i:2:p:124-130

    Download full text from publisher

    File URL:
    Download Restriction: no

    References listed on IDEAS

    1. Adriana Giurgiu, 2008. "The Leading Economic Sectors Building Comparative and Competitive Advantages in Romania's Foreign Trade," Theoretical and Applied Economics, Asociatia Generala a Economistilor din Romania - AGER, vol. 5(5(522)), pages 11-44, May.
    2. GIURGIU Adriana, 2010. "An Overview Of The General Evolution Of The Romanian Foreign Trade After 1989, While Trying To Join The Eu (Ii)," Annals of Faculty of Economics, University of Oradea, Faculty of Economics, vol. 1(2), pages 100-106, December.
    Full references (including those not matched with items on IDEAS)

    More about this item


    drug manufacture; medicine production; Romanian economy; FDI; exports and imports;

    JEL classification:

    • F14 - International Economics - - Trade - - - Empirical Studies of Trade
    • I12 - Health, Education, and Welfare - - Health - - - Health Behavior
    • L52 - Industrial Organization - - Regulation and Industrial Policy - - - Industrial Policy; Sectoral Planning Methods
    • L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology; Plastics


    Access and download statistics


    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ora:journl:v:1:y:2011:i:2:p:124-130. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Catalin ZMOLE) The email address of this maintainer does not seem to be valid anymore. Please ask Catalin ZMOLE to update the entry or send us the correct email address. General contact details of provider: .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.